

New Claims (Attorney Docket No. LeA 36 293)

11. (New) Method of claim 3, wherein detection of said polypeptide(s) is by SELDI-TOF MS.
12. (New) Method of claim 3, wherein specific antibodies or antibodies recognizing said polypeptides are used for detection of said polypeptide(s).
13. (New) Method of claim 3, wherein detection is in a sample comprising CSF, blood, serum, plasma, urine, seminal plasma, nipple fluid, and/or cell extracts of said patient.
14. (New) Method of claim 4, wherein detection of said polypeptide(s) is by SELDI-TOF MS.
15. (New) Method of claim 4, wherein specific antibodies or antibodies recognizing said polypeptides are used for detection of said polypeptide(s).
16. (New) Method of claim 4, wherein detection is in a sample comprising CSF, blood, serum, plasma, urine, seminal plasma, nipple fluid, and/or cell extracts of said patient.

Amended Claims (Attorney Docket No. LeA 36 293)

1. (Currently amended) Method of assessing the state of Alzheimer's disease in a subject comprising ~~detection of at least~~ detecting one or more polypeptides ~~comprised in a selected from the~~ group of polypeptides having, ~~respectively~~, molecular masses of 4824 ± 20 Da, of 7691 ± 20 Da, of 11787 ± 20 Da, of 11988 ± 20 Da, of 13416 ± 20 Da, of 4769 ± 20 Da, of 6958 ± 20 Da, of 6991 ± 20 Da, of 13412 ± 20 Da, of 13787 ± 20 Da, of 17276 ± 20 Da, of 40437 ± 20 Da, of 6895 ± 20 Da, of 6928 ± 20 Da, of 7691 ± 20 Da, of 7769 ± 20 Da, of 7934 ± 20 Da, of 5082 ± 20 Da, of 6267 ± 20 Da, of 6518 ± 20 Da, of 7274 ± 20 Da, and of 8209 ± 20 Da.
2. (Original) Method of claim 1 in which at least 2, or 3, or 4, or 5, or 10 or all polypeptides of said group of peptides are detected.
3. (Currently amended) Method of assessing the state of Alzheimer's disease in a subject comprising ~~detection of at least~~ detecting one or more polypeptides comprising the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 and/or SEQ ID NO:17.
4. (Currently amended) Method of assessing the state of Alzheimer's disease in a subject comprising ~~detection of at least~~ detecting one or more polypeptides ~~comprised in a selected from the~~ group of polypeptides consisting of
 - i) human cystatin C,
 - ii) human beta-2- microglobulin,
 - iii) human myoglobin (new variant)
 - iv) neurosecretory protein VGF,
 - v) a fragment of at least 5 amino acids of human cystatin C,
 - vi) a fragment of at least 5 amino acids of human beta-2-microglobulin,
 - vii) a fragment of at least 5 amino acids of human myoglobin (new variant), and
 - viii) a fragment of at least 5 amino acids of neurosecretory protein VGF.

5. (Original) Method of investigating the progression of Alzheimer's disease in a subject characterized in that a method of any of claims 1 to 4 is performed with at least two distinct samples drawn from the same subject.
6. (Currently amended) Method of ~~any of claims~~ claim 1 to 5, wherein detection of said polypeptide(s) is by SELDI-TOF MS.
7. (Currently amended) Method of ~~any of claims~~ claim 1 to 5, wherein specific antibodies or antibodies ~~recognising~~ recognizing said polypeptides are used for detection of said polypeptide(s).
8. (Currently amended) Method of ~~any of claims~~ claim 1 to 7, wherein detection is in a sample comprising CSF, blood, serum, plasma, urine, seminal plasma, nipple fluid, and/or cell extracts of said patient.
9. (Original) A kit comprising polypeptides having a molecular mass of 4824 ± 20 Da, of 7691 ± 20 Da, of 11787 ± 20 Da, of 11988 ± 20 Da, of 13416 ± 20 Da, of 4769 ± 20 Da, of 6958 ± 20 Da, of 6991 ± 20 Da, of 13412 ± 20 Da, of 13787 ± 20 Da, of 17276 ± 20 Da, of 40437 ± 20 Da, of 6895 ± 20 Da, of 6928 ± 20 Da, of 7691 ± 20 Da, of 7769 ± 20 Da, of 7934 ± 20 Da, of 5082 ± 20 Da, of 6267 ± 20 Da, of 6518 ± 20 Da, of 7274 ± 20 Da, and/or of 8209 ± 20 Da.
10. (Original) A kit comprising a fragment of at least 5 amino acids of human cystatin C, a fragment of at least 5 amino acids of human beta-2- microglobulin, a fragment of at least 5 amino acids of human myoglobin (new variant), and a fragment of at least 5 amino acids of neurosecretory protein VGF.